Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes: a Randomized Controlled Trial (BEYOND)

Next Previous
Search
Trial Profile

Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes: a Randomized Controlled Trial (BEYOND)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary) ; Insulin degludec/liraglutide (Primary) ; Insulin-glargine/lixisenatide (Primary) ; Insulin aspart; Insulin degludec; Insulin glargine; Insulin glulisine; Insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms BEYOND

    • Most Recent Events

    • 01 Feb 2024 Results assessing the results of the scheduled 2-year extension of the BEYOND trial, published in the Endocrine.
    • 17 Sep 2021 Results published in the PubMed Central
    • 20 Oct 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top